close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Allarity Therapeutics, Inc.

< Previous 1 2 3 Next >
News headline image
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics to Present at Biomarkers 2024
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics to Present at Biomarkers Europe 2023
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Reverse Stock Split of Common Stock
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
News headline image
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLR
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.